NCT04958239: A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have at least one measurable lesion outside of central nervous system (CNS)
Exclusions: Patients with active untreated brain metastasis – see trial for details; Patients with known leptomeningeal disease; Patients with previous treatment of agents targeting CD137

Comments are closed.

Up ↑